Development of nanoparticle drug-delivery systems for the inner ear
Development of nanoparticle drug-delivery systems for the inner ear
复制标题
内耳纳米颗粒药物输送系统的开发
DOI：
10.2217/nnm-2020-0198
复制
发表时间：
2020-08-01
期刊：
影响因子：
5.5
通讯作者：
Zha, Dingjun
中科院分区：
文献类型：
--
作者：
An, Xiaogang;Zha, Dingjun
听力损失已成为世界范围内最常见的感觉神经障碍，目前尚无有效的治疗策略。血液迷宫屏障的低通透性和有限的血液供应限制了治疗药物在内耳的有效递送和疗效。基于纳米颗粒（NP）的药物已显示出稳定控释和功能性表面修饰的优势，纳米颗粒给药系统已成为研究热点。本文综述了基于不同NPs在耳蜗内的生物相容性和安全性的新型靶向给药系统的发展，以及它们的处方方法和途径的优缺点。我们相信靶向np给药系统将是治疗听力损失的有效方法。
Hearing loss has become the most common sensory nerve disorder worldwide, with no effective treatment strategy. Low-permeability and limited blood supply to the blood-labyrinth barrier limit the effective delivery and efficacy of therapeutic drugs in the inner ear. Nanoparticle (NP)-based drugs have shown benefits of stable controlled release and functional surface modification, and NP-based delivery systems have become a research hotspot. In this review, we discuss the development of new targeted drug-delivery systems based on the biocompatibility and safety of different NPs in the cochlea, as well as the advantages and disadvantages of their prescription methods and approaches. We believe that targeted NP-based drug-delivery systems will be effective treatments for hearing loss.